180 related articles for article (PubMed ID: 35865814)
1. Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer.
Sarkar P; Malik S; Banerjee A; Datta C; Pal DK; Ghosh A; Saha A
Front Cell Infect Microbiol; 2022; 12():894777. PubMed ID: 35865814
[TBL] [Abstract][Full Text] [Related]
2. [Herpes viruses and human papillomavirus in prostate cancer: first results].
Mikhaleva L M; Kamalov A A; Karpov V K; Okhobotov D A; Akopyan E P; Shakhpazyan N K; Shaparov B M; Nesterova O Y; Martirosyan L K; Ekhoyan M M; Osmanov O A
Urologiia; 2023 Dec; (6):95-101. PubMed ID: 38156690
[TBL] [Abstract][Full Text] [Related]
3. Prostate Infiltration by Treg and Th17 Cells as an Immune Response to
Radej S; Szewc M; Maciejewski R
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012113
[TBL] [Abstract][Full Text] [Related]
4. Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues.
Ahmed K; Sheikh A; Fatima S; Haider G; Ghias K; Abbas F; Mughal N; Abidi SH
Sci Rep; 2022 Jun; 12(1):10399. PubMed ID: 35729214
[TBL] [Abstract][Full Text] [Related]
5. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
7. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
8. Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer.
Nahand JS; Khanaliha K; Mirzaei H; Moghoofei M; Baghi HB; Esghaei M; Khatami AR; Fatemipour M; Bokharaei-Salim F
BMC Cancer; 2021 Aug; 21(1):926. PubMed ID: 34399719
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus and Epstein Barr virus in prostate cancer: Koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer.
Whitaker NJ; Glenn WK; Sahrudin A; Orde MM; Delprado W; Lawson JS
Prostate; 2013 Feb; 73(3):236-41. PubMed ID: 22851253
[TBL] [Abstract][Full Text] [Related]
10. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
11. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
Zambra FM; Biolchi V; Brum IS; Chies JA
Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
13. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
14. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
Dülgeroğlu Y; Eroğlu O
Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
[TBL] [Abstract][Full Text] [Related]
15. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
16. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
17. [Phenotyping of angiotensin-converting enzyme in the prostate in patients with prostate cancer and benign prostatic hyperplasia].
Mamedov VN; Danilov SM; Samokhodskaya LM; Okhobotov DA; Kamalov DM; Melnikov N; Karpov VK; Kadrev AV; Kamalov AA
Urologiia; 2020 Nov; (5):20-27. PubMed ID: 33185341
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human papillomavirus infections in prostatic disease: a cross-sectional study in Iran.
Ghasemian E; Monavari SH; Irajian GR; Jalali Nodoshan MR; Roudsari RV; Yahyapour Y
Asian Pac J Cancer Prev; 2013; 14(5):3305-8. PubMed ID: 23803120
[TBL] [Abstract][Full Text] [Related]
19. A non-socially-sensitive predictive model of prostate cancer for Asian males with benign prostatic hyperplasia: A multi-site cross-sectional case-control study.
Chang HJ; Moi SH; Chan YJ; Lan TY
PLoS One; 2023; 18(12):e0295608. PubMed ID: 38079423
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.
Mengus C; Le Magnen C; Trella E; Yousef K; Bubendorf L; Provenzano M; Bachmann A; Heberer M; Spagnoli GC; Wyler S
J Transl Med; 2011 Sep; 9():162. PubMed ID: 21943235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
